Very smart move, helps reinforce the product's position as a steroid commodity with payers versus clinical positioning. Now just need to cut the price by 90% to complete this brilliant piece of strategery.
Please don't give them anymore brilliant ideas. Unfortunately for all of us, they have plenty of their own.
